Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population

Trial Profile

Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Antiplatelets
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms IDEAL-LM
  • Most Recent Events

    • 01 May 2017 Rationale and study design, published in the American Heart Journal.
    • 21 Mar 2016 Accrual to date is 26% as reported by United Kingdom Clinical Research Network.
    • 11 Dec 2015 Accrual to date is 19% as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top